Given that the presence of the BRD2‐FTH1 interaction affects the intracellular amount of BRD2, we wondered if disrupting the BRD2‐FTH1 complex could alter NSCLC cells' response to the prototype BET inhibitor, JQ1. The gene discussed is BRD2; the disease is non-small cell lung carcinoma.